Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07816770) titled 'MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Fudan University
Condition:
Metastatic Non-Clear Cell Renal Cell Carcinoma
Metastatic Renal Medullary Carcinomas
Intervention:
Drug: Toripalimab
Drug: Axitinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 20, 2026
Target Sample Size: 30
To know more, visit https:/...